<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Chalmers-Gothenburg_Parts skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Chalmers-Gothenburg/Parts</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Interlab - iGEM Chalmers-Gothenburg 2018</TITLE></P><NAV id="navbar" class="mynav navbar-expand-md bg-dark navbar-dark sticky-top"><DIV class="collapse navbar-collapse justify-content-around" id="collapsibleNavbar"><UL class="navbar-nav align-items-center"><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" id="navbardrop-project" role="button" data-toggle="dropdown">
        PROJECT
      </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Description" style="color:#16181b">Project Overview</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Project" style="color:#16181b">Project Summary</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Achievements" style="color:#16181b">Achievements</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" id="navbardrop-wetlab" data-toggle="dropdown">
        LABWORK
      </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Attachment" style="color:#16181b">Binding</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Detection" style="color:#16181b">Detection</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Treatment" style="color:#16181b">Treatment</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/InterLab" style="color:#16181b">InterLab</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Parts" style="color:#16181b">BioBricks</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Protocols" style="color:#16181b">Protocols</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Safety" style="color:#16181b">Safety</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" id="navbardrop-hp" data-toggle="dropdown">
        HUMAN PRACTICES
      </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Human_Practices" style="color:#16181b">Human Practices</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Collaborations" style="color:#16181b">Collaborations</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Outreach" style="color:#16181b">Outreach</A></DIV></LI></UL><UL class="navbar-nav align-items-center"><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" id="navbardrop-model" data-toggle="dropdown">
        MODELING
      </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Model" style="color:#16181b">Model Overview</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/ModelConstruction" style="color:#16181b">Model Design</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" id="navbardrop-team" data-toggle="dropdown">
        PEOPLE
      </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Team" style="color:#16181b">Team</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Supervisors" style="color:#16181b">Supervisors</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Sponsors" style="color:#16181b">Sponsors</A><A class="dropdown-item" href="https://2018.igem.org/Team:Chalmers-Gothenburg/Attributions" style="color:#16181b">Attributions</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" id="navbardrop-social" data-toggle="dropdown">
        SOCIAL MEDIA
      </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://www.facebook.com/chalmersigem" style="color:#16181b">Facebook</A><A class="dropdown-item" href="https://www.instagram.com/chalmersigem" style="color:#16181b">Instagram</A><A class="dropdown-item" href="https://twitter.com/igemchalmers" style="color:#16181b">Twitter</A></DIV></LI></UL></DIV></NAV><DIV class="container-fluid" style="margin-top:30px;"><DIV class="row"><DIV class="col-lg-8" style="text-align:justify"><DIV class="row"><DIV class="col-12"><H1 style="text-align:center">
              BioBricks
            </H1><H1>Kozak-Aga2-Linker-GFP</H1><P>In order to express GFP at the surface of our yeast cells, the yeast surface anchoring protein Alpha-Agglutin 2 (Aga2) was fused to the 3’-end of GFP. Aga2 binds with a double disulfide bond to Alpha-Agglutin 1 (Aga1) in the cell wall of the yeast. To increase chances of expression a Kozak sequence was added at the 5’-end of the Aga2 and to allow for better protein function of the individual proteins, we also added a flexible linker (GGGS)x3 in between the proteins. For more information on this BioBrick, please visit the prts registery <A href="http://parts.igem.org/Part:BBa_K2625000">here</A> or our results page <A href="https://2018.igem.org/Team:Chalmers-Gothenburg/Attachment">here</A></P><FIGURE style="text-align:center;"><FIGCAPTION><I><B>Figure 1:</B> Plasmid design with Aga2, GFP, the spacer, and the Kozak sequence. The plasmid of origin is pSB1C3.</I></FIGCAPTION></FIGURE><H1>Secretion Factor α pro + MYR1 Myrosinase</H1><P>
This part was developed by our team to be used as a way to kill colon cancer cells. Myrosinase belongs to a family of enzymes involved in the plant defense. It can catalyze the hydrolysis of glucosinolates. The final product that derives from this hydrolysis has been proved to inhibit carcinogenesis and tumorigenesis in certain circumstances. 
The Myrosinase itself is coupled to a secretion peptide since it needs to be present in the media for it to interact with the glucosinolates. A Kozak sequence was also introduced at the begining of the protein to enhance expression. Please check out our entry in the parts registry <A href="http://parts.igem.org/Part:BBa_K2625001">here</A> or our results page <A href="https://2018.igem.org/Team:Chalmers-Gothenburg/Treatment">here</A> for more information. </P><FIGURE style="text-align:center;"><FIGCAPTION><I><B>Figure 2:</B> Plasmid design with Alphapro and Myrosinase(Myr1), the spacer and the Kozak sequence. The plasmid of origin is from pSB1C3.</I></FIGCAPTION></FIGURE></DIV></DIV></DIV></DIV></DIV><DIV id="footer"><FOOTER><H4 style="font-size:12pt;">
    CONTACT INFORMATION: 
  </H4><DIV><P style="font-size:10pt;">
      CHALMERS University of Technology, Gothenburg, Sweden, igemgothenburg@gmail.com   
</P><SPAN><A style="font-size:10pt;" href="https://www.facebook.com/chalmersigem">Facebook</A><A style="font-size:10pt;" href="https://www.instagram.com/chalmersigem">Instagram</A><A style="font-size:10pt;" href="https://twitter.com/igemchalmers">Twitter</A></SPAN></DIV></FOOTER></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>